Certara signs definitive agreement to acquire Chemaxon; reiterates 2024 guidance

Certara, Inc.

Definitive agreement to acquire Chemaxon, a cheminformatics software provider; no deal value disclosed.
Transaction expected to close in H2 2024, subject to regulatory approval and customary conditions.
Chemaxon expected to generate >$20M software revenue in 2024; adjusted EBITDA margin near Certara's corporate average by end 2025.
Certara reiterates 2024 revenue, adjusted EBITDA margin (31-33%), and adjusted diluted EPS guidance from May 7 earnings call.
Acquisition expands Certara's drug discovery biosimulation portfolio; long-term partnership with Chemaxon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.